afternoon, quarter good during and pleased Sara, our I’m first you, Thank conference call. highlight XXXX to Iovance at progress everyone. today’s
During infiltrating head cervical, and XXXX, expand lymphocytes and multiple we tumor including have cell metastatic melanoma, neck cancers. continued our or lung across Iovance to advance non-small indications TIL platform and
top BLA XXXX. FDA melanoma, support submission. lifileucel or for potency candidate our metastatic product we the biologics to TIL and related is with lead FDA the planned of license of additional in our to our assay submission completed For priority potency Resolution assays a application, of information
The for C-XXX-XX demonstrating data X will And our completed lifileucel also Cohort from responses additional dosing updated lifileucel. in updates, data one-time for our and in We at treatment indications, show presented X as was be data Cohort patient cancer. cervical we AACR clinical with and new XXXX we as at we study ongoing presented in on Cohort X durable advanced ASCO reported XXXX.
in multiple we TIL lung believe stage our consented cancer, of registration-directed coupled TIL our from across data validate growing to Iovance of anti-PD-X potential multiple study sites of stages TIL LN-XXX disease IOV-LUN-XXX For activate results non-small and and body patients. clinical therapy. We that for with cell the significance earlier the cancers late and of combination for therapy and the Iovance broad continue
toward in I to team have critical year all and We experience. our An XXX pre-commercial the manufacturing XX% confident of commitment of towards at least the our also this furthering of am address very our quality execute impressive patients. mission. employees therapy cell more cancer than of continue to deliver internal activities and a need to
our progress. minutes to updates. will today, On highlighting the like few Then a our melanoma. I begin call let indications first will spend our and manufacturing advanced program clinical lifileucel Friedrich data I pivotal for with review I would lead recent
diagnosed As In melanoma melanoma and for approximately United States. type X,XXX U.S our the calls, discussed is patients common previous each alone metastatic the a cancer. XXX,XXX of in in account year deaths metastatic skin
XX% study. study are duration most therapies plenary treatments used saw one-time was updated of commonly focused in that for median about that for follow-up enthusiastic of highlighted the We to data session. as growing clinical who treat melanoma was XX.X metastatic XX.X% care data from continue Research long-term as response, presented the not AACR Cohort median response physicians or options response The follow-up. meeting, the population and X the trial at annual AACR clinical to We, our on Cancer need very at at patients following be study have a of very of C-XXX-XX exhausted patients. metastatic melanoma rates showed lifileucel including available with in durability patients. we deepening difficult data KOLs, of a the of in reached Furthermore, the C-XXX-XX months well Association their the at alternative American response remain At overall continued and
X will data Society for in manuscript ASCO of a in been growth For Clinical X, or accepted for X Detailed and June. be only in at the post-anti-PD-X chemotherapy Further Oncology X the a meeting overall patient publication a option has oncology to high upcoming population in response the offers only American available X rate to and forthcoming highlighted annual and months. journal. also currently peer-reviewed Cohort Cohort impact is X% of XX% updates Cohort survival
combination therapy to Turning lifileucel TIL about meeting, of and for pembrolizumab available patients. is provided. we being therapies into TIL tested sharing in with treatment Combination are metastatic the moving and with data Iovance clinical one Iovance's clinical combination anti-PD-X of ASCO such XXXX with earlier and upcoming second the excited naive naive data and Melanoma patients TIL at main of toward goals clinical setting in earlier is anti-PD-X settings. is melanoma lines are
assays As a the FDA for reaching potency with top previously priority is agreement for lifileucel on mentioned, Iovance.
available. BLA from the While we the provide plan We depends staying on in length to XXXX. submission agency, updates continue of a BLA feedback submission time prepared when until for
cancer. this a known Our in is BLA cervical also second investigating submission program pivotal in study metastatic as lifileucel, C-XXX-XX support LN-XXX to now
upcoming completed first the post-anti-PD-X evaluating co-pivotal both is X was chemotherapy, in dosing Cohort X X, cancer. cancer with to in in that treatment lifileucel believe quarter, patient the During includes lifileucel post potential landscapes and Cohort BLA the a which that may patients. strengthen Cohort addition cervical reflects submission expected cervical We label
in before, and steps cervical mentioned around key follow-up in resolution amount melanoma potency with BLA the FDA our the are cancer lifileucel of submission clinical of the data for assay dialogue toward indications. have we the As
has and Track As Fast cancer. lifileucel therapy for granted previously breakthrough both the a FDA reminder, designation cervical and
manufacturing shell moved start Process core well and initial manufacturing meet manufacturing late in of patients center, place necessary has from in and Commercial demand have rooms now on exterior XXXX ICTC, indications. academic yielding Turning in the the activities support manufacturing or remains track for are XXXX. and clean GMP clinical centralized our capacity cell a as shorter, in transformed TIL of have commenced utilities of TIL and to as Iovance construction the X,XXXs TIL lengthy equipment completed available multiple a clean product. in. of to room have process process to cryopreserved for Iovance to the scalable, up with a Iovance facility, therapy we we to
X continuing XX%. above success XX Our more with than is a Iovance To date, TIL Gen patients rate process received days. have XXX
granted studies. to cell manufacturing generation composition relating TIL include with explored cohort and well shorter tumor products, process the A Granted patent process in composition also including of of manufacturing X non-small allowed is selected broad melanoma modification XX augment to and of combination patents transient towards X treatment U.S the methods to a covered our patients patients of timelines built include checkpoint of We cancers and stable intellectual as XXXX. being our in property by dosing the IOV-LUN-XXX is cancer are third We’ve more TIL methods TIL, further a continued range and a the with or of expected exclusivity patents day international looking forward Gen patents. patients through of applications Gen cryopreservation than and efficiencies. genetic two the digest which TIL X granted and are directed and receiving potential also TIL manufacturing Iovance improve initiated metastatic Gen as inhibitors. where in The clinical in a to Gen IOV-COM-XXX Iovance fragment study. TIL clinical and cohort X study has lung manufacturing, patient XX and also or
from additional Institutes for have of including press cytokines Health, In and or TIL similar release, IL-XX rights technology. and addition, this as National patent in noted tethered afternoon's IL-XX technology we licensed NIH
to expanded and intellectual We all field our relationship We may leadership related with advancement our and the cancers. also worldwide of that believe expanded TIL solidify property. this license use further NIH in of
Turning we pre-commercial disciplined our remain gated commercial to readiness. preparations, in launch our to approach
access, coverage to for other Our team readiness the training, foundation and commercialization activities. patient payer core continues commercial site build
are We expand on potency these scale with the efforts pending FDA and well-positioned across alignment rapidly to our areas assay.
team site U.S advocacy program capabilities. peer with and until conferences build is key preparation and patient to leaders groups educational Commercial This affairs at ensure to scientific continues in launch. maintains reviewed and engagement to in opinion team clinical and work medical awareness their line leading team major service the commercial for publications. with TIL cancer Our communication partnering centers
which will the submission program, upon BLA to expand ensure we further treatment Our can and administer supplier the upon approval. FDA team regimen onboarding cross is lifileucel training designed
new XX centers Medicaid international lifileucel. for procedure engage payers to ensure Services, lifileucel. coding codes team CMS, have of proposed or or two access recently ICD to XXth market Very diseases, access for and system Medicare the revision, Our continues classification to patients
The CMS map the also TIL in lifileucel XX developing T on has of CAR cell IOVANCECares need existing include and to leadership is if time commitment T. CMS's to the recognition TIL. expand lifileucel our of other at Additionally, providers lifileucel T immunotherapy believe immunotherapies for proposal care. to value cell CMS's for CAR to proposed XX proposed MS-DRG finalized, strengthen and for CMS to remains launch. existing Iovance appropriate XX. to proposal, and track. and to the patients including therapy reimbursement to which We MS-DRG We from reimbursement MS-DRG The that is hospital team to also of appreciate beyond ensure the program CAR potential cell access Iovance Iovance therapies
to call and chain capabilities. to the designed support Friedrich? of customer and the platform Our deliver cell IOVANCECares I to now to will journey. is patient identity pass treatment a throughout and centric custody patient Friedrich chain our both system, update. outline be lifileucel goal ordering clinical best-in-class of is
